HIV

HIV-1 Rev (34-50) (HIV-1 rev Protein (34-50)) is a 17-amino acid peptide with anti-HIV-1 activity, derived from the Rev-responsive element-binding domains of Rev in HIV-1.

HIV-1 Inhibitor 18A (HIV-1 Inhibitor-18A) specifically inhibits the entry of multiple HIV-1 isolates.

HIV-1 TAT (48-60) Acetate, a commonly used membrane-permeable carrier peptide, is an arginine-rich basic peptide derived from the human immunodeficiency virus (HIV-1 Tat) protein that enables intracellular delivery of compounds.

HIV-1 Nef-IN-1 is an inhibitor of the HIV-1 Nef protein, effectively competing for Nef-SH3Hck interactions (Kd: 6.7 μM).

HIV-1 inhibitor-6 (3-Pyridinecarboxamide, 1,4-dihydro-1-methyl-N-(5-nitro-1,2-benzisothiazol-3-yl)-4-oxo-) is a potent HIV-1 pre-mRNA selective splicing inhibitor that blocks HIV replication.

HIV-1 inhibitor-54 is a potent inhibitor of WT HIV-1 (strain IIIB) in MT-4 cells, demonstrating anti-HIV activity with an EC50 of 32 nM. [HIV-1 inhibitor-54 can be used to study viral infections.]

HIV-1 integrase inhibitor 8 is an inhibitor of HIV-1 integrase, a critical enzyme necessary for the integration step in HIV replication [1].

HIV-IN-6 is an HIV viral inhibitor that inhibits the replication of the HIV virus.HIV-IN-6 has anti-HIV viral activity and works by targeting Src family kinases (SFK) (e.g., Hck) that interact with the viral Nef protein.

HIV-1 inhibitor-3 is an HIV infection inhibitor.

HIV-1 integrase inhibitor 7 is a potent inhibitor of HIV-1 integrase (IC50: 33.3 nM).

Hiv-1 integrase inhibitor is an effective anti-HIV drug.

HIV-1 integrase inhibitor 3 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 2.7 nM.

HIV-1 integrase inhibitor 4 is an HIV-1 integrase strand transfer (INST) inhibitor with an IC50 of 3.7 nM.

HIV Protease Substrate 1 is a fluorogenic compound that offers insights into the enzymatic activity of HIV protease, making it a valuable tool for studying this aspect.

HIV-1 Inhibitor-53 is a dual inhibitor targeting both the HIV-1 protease (PR) with an IC50 value of 1.93 nM and reverse transcriptase (RT) with an IC50 of 2.35 μM. It serves as a potent agent for AIDS research [1].

HIV-1 protease-IN-7 (compound 16) is an orally active HIV-1 protease inhibitor with an IC50 of 3.52 nM and an EC50 of 37 nM [1].

HIV-1 protease-IN-8 (compound 34b) is a potent inhibitor of the HIV-1 protease enzyme with an IC50 of 0.32 nM. It exhibits IC50 values of 0.29 μM for the wild-type HIV-1 (HIV-1 NL4-3) and 1.90 μM against a drug-resistant variant (HIV-1 MDR), indicating strong antiviral activity against both strains [1].

HIV-1 protease-IN-9 (compound 5b), a potent HIV-1 protease inhibitor, exhibits strong antiviral efficacy with a dissociation constant (K_i) of 0.028 nM and a half-maximal inhibitory concentration (IC_50) of 66.8 nM [1].

HIV-1 protease-IN-11 (compound 34a), an HIV-1 protease inhibitor, demonstrates potent inhibition with an IC50 of 0.41 nM and maintains substantial efficacy against a drug-resistant variant [1].

HIV-1 protease-IN-12 (compound 35b) is a potent HIV-1 protease inhibitor with an IC50 value of 0.51 nM, demonstrating efficacy against drug-resistant variants [1].

HIV gag peptide (197-205) is an H-2Kd-restricted epitope derived from the p24 portion of the HIV-1 gag protein, composed of amino acids 197-205 (AMQMLKETI).

HIV p17 Gag (77-85) is an attractive target for molecular intervention due to its involvement in the viral replication cycle at both pre- and postintegration levels. In current experiments, we targeted p17 by intracellularly expressing a cDNA encoding an Ab to p17.

MPG, a 27-amino acid peptide compound, is derived from the fusion peptide domain of HIV-1 gp41 and the nuclear localisation sequence of SV40 large T antigen. As a potent delivery agent, MPG enables efficient and widespread transport of nucleic acids and oligonucleotides into cultured cells.

R15K, HIV-1 Inhibitory Peptide is a polypeptide molecule with the sequence RIQRGPGRAFVTIGK.